Literature DB >> 24957159

Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy.

Hye Won Lee1, Eun Jin Yoo1, Beom Kyung Kim2, Seung Up Kim2, Jun Yong Park2, Do Young Kim2, Sang Hoon Ahn3, Kwang-Hyub Han3.   

Abstract

OBJECTIVES: In the era of antiviral therapy, the prognostic significance of serum hepatitis B virus (HBV) DNA level as a biological gradient substantially diminished, as most patients can achieve complete virological response (CVR). We aimed to investigate the predictive roles of liver stiffness (LS) for liver-related events (LREs) among patients with CVR.
METHODS: We analyzed 192 patients with chronic HBV infection who achieved CVR (defined as HBV DNA <20 IU/ml) through entecavir therapy. LS values at CVR were measured using transient elastography. LREs were defined as any cirrhotic complication, hepatocellular carcinoma, and liver-related mortality.
RESULTS: The median age of the patients was 49 years, and 134 (69.8%) were male. The median LS value at CVR was 8.8 kPa. During follow-up, LREs occurred in 25 (13.0%) patients. When the population was stratified into three groups (<8.0 kPa, 8.0-13.0 kPa, and >13.0 kPa), cumulative LRE incidences increased significantly in association with LS values (log-rank test, P=0.001). Patients with an LS value >13.0 kPa (hazard ratio (HR)=12.336, 95% confidence interval (CI) 1.335-114.010; P=0.027) and 8.0-13.0 kPa (HR=8.832, 95% CI 1.092-71.432; P=0.041) were at significantly greater risk compared with those with an LS value <8.0 kPa. On multivariate analysis, age and LS values were seen to be independent predictors (all P<0.05). When LS values were incorporated into the REACH-B scoring model instead of serum HBV DNA level, a better predictive performance was seen compared with a conventional approach (areas under the receiver operating characteristic curve, 0.814 vs. 0.629, respectively).
CONCLUSIONS: LS values at CVR are useful for predicting forthcoming LRE development. Thus, in the era of potent antiviral therapy, tailored surveillance strategies might be established based upon LS values at CVR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24957159     DOI: 10.1038/ajg.2014.157

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  35 in total

Review 1.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

2.  Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients.

Authors:  Vincent Wai-Sun Wong; Pietro Lampertico; Victor de Lédinghen; Pik Eu Chang; Seung Up Kim; Yongpeng Chen; Henry Lik-Yuen Chan; Giampaolo Mangia; Juliette Foucher; Wan Cheng Chow; Sang Hoon Ahn; Jinlin Hou
Journal:  Dig Dis Sci       Date:  2015-01-07       Impact factor: 3.199

3.  Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis.

Authors:  Shanshan Wu; Zhirong Yang; Jialing Zhou; Na Zeng; Zhiying He; Siyan Zhan; Jidong Jia; Hong You
Journal:  Hepatol Int       Date:  2018-11-15       Impact factor: 6.047

Review 4.  Clinical applications, limitations and future role of transient elastography in the management of liver disease.

Authors:  Pik Eu Chang; George Boon-Bee Goh; Jing Hieng Ngu; Hiang Keat Tan; Chee Kiat Tan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

5.  Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.

Authors:  Mi Young Jeon; Hye Won Lee; Seung Up Kim; Ja Yoon Heo; Sojung Han; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2017-02-21       Impact factor: 6.047

Review 6.  Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Giacomo Emanuele Maria Rizzo; Giuseppe Cabibbo; Antonio Craxì
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

7.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2022-04-01

8.  Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis.

Authors:  Luca Rinaldi; Antonio Ascione; Vincenzo Messina; Valerio Rosato; Giovanna Valente; Vincenzo Sangiovanni; Rosa Zampino; Aldo Marrone; Luca Fontanella; Nicolina de Rosa; Pasquale Orabona; Carmela Buonomo; Antonio Chirianni; Luigi Elio Adinolfi; Guido Piai
Journal:  Infection       Date:  2018-01-15       Impact factor: 3.553

Review 9.  The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.

Authors:  Jung Hwan Yu; Soon Gu Cho; Young-Joo Jin; Jin-Woo Lee
Journal:  Clin Mol Hepatol       Date:  2021-11-26

Review 10.  Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update.

Authors:  James Lok; Kosh Agarwal
Journal:  Viruses       Date:  2021-07-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.